Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of AbataceptReportar como inadecuado




Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

1 GRC-08 EEMOIS - Service de rhumatologie CHU Pitié Salpêtrière 2 iPLESP - Institut Pierre Louis d-Epidémiologie et de Santé Publique 3 Bristol-Myers Squibb, Rueil-Malmaison 4 Bristol-Myers Squibb, Princeton 5 Stanford University School of Medicine Stanford

Abstract : Introduction: A post hoc analysis of three randomized controlled trials of abatacept in rheumatoid arthritis RA was conducted to explore the effect of abatacept on fatigue in RA and its correlation with other outcomes.Methods: In this analysis of AGREE early RA and AIM and ATTAIN established RA, changes in baseline fatigue 0–100 mm scale, pain, sleep AIM and ATTAIN only and Disease Activity Score DAS 28 C-reactive protein; CRP were calculated at days 29, 85, and 169. Agreement between improvements ≥minimum clinically important differences MCID in fatigue and other outcomes were evaluated using agreement statistics kappa in each study and at each time point.Results: Of 1536 patients mean disease duration: 6.2 months AGREE, 8.5 years AIM, 12.2 years ATTAIN, mean SE decreases in fatigue from baseline to day 169 with abatacept were 28.9 1.7, 25.3 1.2, and 21.9 1.6 in AGREE, AIM, and ATTAIN, respectively, with corresponding decreases of 16.0, 13.7, and 13.4 at day 29. Most patients 67.8%; 624-920 reported improvements ≥MCID in fatigue with abatacept at day 169; 79.2% 671-847 and 57.8% 388-671 reported improvements ≥MCID in pain and sleep, respectively; 18.9% 158-836 were in DAS28 CRP remission. Agreement between improvement in fatigue and other outcomes was low kappa range 0.30–0.51 pain, 0.14–0.26 sleep, and 0.02–0.12 DAS28 CRP remission.Conclusions: Abatacept resulted in rapid improvements in fatigue and pain in patients with RA. However, low agreement between improvements in these outcomes indicates that fatigue and other outcomes including pain and sleep may represent different domains of response.





Autor: Laure Gossec - Souhila Ahdjoudj - Evo Alemao - Vibeke Strand -

Fuente: https://hal.archives-ouvertes.fr/



DESCARGAR PDF




Documentos relacionados